Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment
Business Wire India Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in…